PublicationFDA

Preparing a Drug Registration for the US and the EU: Parallel or sequential applications? – Part 1

An overview of the main challenges faced by marketing authorisation applicants for the conversion of a dossier from one region to another, and deciding between a sequential and a parallel preparation.

Nathalie Boeglin, Alice Rolland, Frederic Pailloux and David Uguen.

February 2015 – Regulatory Rapporteur

Click here for Part 2

Download the full publication now

Fill in the form to download the content

*I have read and agreed to the Terms of Use and the Privacy Policy.Yes, I would like to receive communications regarding VCLS services and events

publication by

FRÉDÉRIC PAILLOUX, PHARM.D., M.SC.

Nathalie Boeglin

Director Regulatory Science Drugs & Biologics

Alice Rolland

Regulatory Scientist Drugs and Biologics

David Uguen

Executive Director Drugs and Biologics

Preparing a Drug Registration for the US and the EU: Parallel or sequential applications? – Part 1

Download the full publication now

publication by

How to master both Marketing Authorization and Joint Clinical Assessment successfully?

Navigating the New FDA Draft Guidance on Platform Technologies: An Overview for Life Sciences Companies

Accelerating Innovation: FDA Expedited Programs 101

Achieve Success for Your First US Product Application – Pathway to IND

Preparing a Drug Registration for the US and the EU: Parallel or sequential applications? – Part 1

Download the full publication now

publication by

More resources

How to master both Marketing Authorization and Joint Clinical Assessment successfully?

Navigating the New FDA Draft Guidance on Platform Technologies: An Overview for Life Sciences Companies

Accelerating Innovation: FDA Expedited Programs 101

Achieve Success for Your First US Product Application – Pathway to IND